Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | ATM | Q13315 | 1/20 | 0.64 |
| ▸ | USP2 | O75604 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 2/20 | 0.57 |
| ▸ | IKBKB | O14920 | 1/20 | 0.56 |
| ▸ | CHUK | O15111 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3253197 | 0.98 | MAPT (0.96) | MAPTKMT2AATMUSP2L3MBTL1 | |
| SCHEMBL5304087 | 0.93 | MAPT (0.87) | MAPTKMT2AATMUSP2L3MBTL1 | |
| SCHEMBL4580893 | 0.86 | ATM (0.81) | MAPTKMT2AATMUSP2L3MBTL1 | |
| SCHEMBL10355428 | 0.86 | ATM (0.81) | MAPTKMT2AATMUSP2L3MBTL1 | |
| SCHEMBL5204276 | 0.84 | PKM (0.73) | MAPTKMT2AUSP2ALDH1A1MEN1 | |
| SCHEMBL6797955 | 0.84 | MAPT (0.71) | MAPTKMT2AATMUSP2L3MBTL1 | |
| Hydrochloric Acid SCHEMBL2267301 | 0.82 | PKM (0.71) | MAPTKMT2AUSP2ALDH1A1MEN1 | |
| SCHEMBL2705461 | 0.82 | L3MBTL1 (0.83) | MAPTKMT2AATMUSP2L3MBTL1 | |
| SCHEMBL5251954 | 0.82 | L3MBTL1 (0.77) | MAPTKMT2AATMUSP2L3MBTL1 | |
| SCHEMBL13489662 | 0.82 | MAPT (0.70) | MAPTUSP2L3MBTL1ALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743446-A1 | NITRO-CONTAINING COMPOUNDS THAT KILL MYCOBACTERIA | Board of Trustees of Michigan State University (US) | 2026-05-20 | — | — | EP | disclosed |
| WO-2025015066-A1 | NITRO-CONTAINING COMPOUNDS THAT KILL MYCOBACTERIA | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2025-01-16 | — | — | WO | disclosed |
| CN-117720528-A | Oxadiazole sulfonamide compound containing pyrazole structure, and preparation method and application thereof | 贵州大学 | 2024-03-19 | — | — | CN | disclosed |
| CN-117586179-A | GPR183 antagonist and synthetic method and application thereof | 中国人民解放军海军特色医学中心 | 2024-02-23 | — | — | CN | disclosed |
| CN-114634465-B | Pentadienone derivative containing sulfonyl piperazine as well as preparation method and application thereof | 贵州大学 | 2023-05-30 | — | — | CN | disclosed |
| CN-114085199-B | Chalcone derivative containing sulfonyl piperazine as well as preparation method and application thereof | 贵州大学 | 2023-04-21 | — | — | CN | disclosed |
| CN-114634465-A | Sulfonyl piperazine-containing pentadiene ketone derivative and preparation method and application thereof | 贵州大学 | 2022-06-17 | — | — | CN | disclosed |
| CN-114085199-A | Chalcone derivative containing sulfonyl piperazine and preparation method and application thereof | 贵州大学 | 2022-02-25 | — | — | CN | disclosed |
| US-9663537-B2 | Chemokine receptor antagonists and methods of use | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160031908-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2016-02-04 | — | — | US | disclosed |
| US-6376506-B1 | REACTING SULFAMOYL OXAZOLIDONE WITH (1,2,3,4)-TETRAHYDRO-BETA-CARBOLINE TO FORM INHIBITOR; USED TO TREAT ARTHRITIS, OSTEOPOROSIS, PERIODONTAL DISEASE, CARDIOVASCULAR DISEASES, MULTIPLE SCLEROSIS, AND TUMORS | SYNTEX (U.S.A.) LLC | 2002-04-23 | — | — | US | disclosed |
| US-6329385-B1 | ANTIINFLAMMATORY AGENTS, ANTIARTHRITIC AGENTS, VIRAL DISEASES AND GASTROINTESTINAL DISORDERS | MILLENNIUM PHARMACEUTICALS, INC. | 2001-12-11 | — | — | US | disclosed |
| WO-2001009138-A2 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2001-02-08 | — | — | WO | disclosed |
| EP-1049700-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | Millennium Pharmaceuticals, Inc. (US) | 2000-11-08 | — | — | EP | disclosed |
| CN-1272107-A | Benzamidine derivatives as factor Xa inhibitors | MERCK PATENT GMBH (DE) | 2000-11-01 | — | — | CN | disclosed |
| WO-1999037651-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | MILLENIUM PHARMACEUTICALS, INC. (US) | 1999-07-29 | — | — | WO | disclosed |
| EP-0242957-B1 | 1-SUBSTITUTED ALKYL-1, 2-DIHYDRO-2-PYRAZINONE DERIVATIVES | TOYO JOZO KABUSHIKI KAISHA (JP) | 1990-09-12 | — | — | EP | disclosed |
| US-4877875-A | ANTIAGGLOMERANTS, VASODILATORS | TOYO JOZO KABUSHIKI KAISHA (JP) | 1989-10-31 | — | — | US | disclosed |
| US-4837319-A | VASODILATORS, ANTICOAGULANTS | TOYO JOZO KABUSHIKI KAISHA (JP) | 1989-06-06 | — | — | US | disclosed |
| EP-0242957-A1 | 1-Substituted Alkyl-1, 2-Dihydro-2-Pyrazinone derivatives | TOYO JOZO KABUSHIKI KAISHA (JP) | 1987-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031908-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | ACKR3, CCR2, CXCR2 | MAPT 4776/4885KMT2A 4568/4885ATM 4394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.